Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To evaluate and characterize a single weight-based dose of rasburicase followed by oral allopurinol for treatment of tumor lysis syndrome as well as to determine the effect on serum creatinine

Trial Profile

To evaluate and characterize a single weight-based dose of rasburicase followed by oral allopurinol for treatment of tumor lysis syndrome as well as to determine the effect on serum creatinine

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2018

At a glance

  • Drugs Rasburicase (Primary) ; Allopurinol
  • Indications Tumour lysis syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Jul 2018 New trial record
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top